Liječnički vjesnik, Vol. 132 No. 1-2, 2010.
Pregledni rad
MOLECULAR BASIS OF BREAST CANCER RELATED TO BRCA 1 AND BRCA2 GENES: CHARACTERISTICS AND TARGETING THERAPY
SONJA LEVANAT
Mirela LEVAČIĆ CVOK
Sažetak
Breast cancer is one of the most frequent tumors in women, and BRCA1 and BRCA2 genes play a major role in the hereditary susceptibility for this disease. Until the age of 70 women carrying a mutation in BRCA1 or BRCA2 gene have a 45–85% probability of developing breast cancer, and 11–62% probability of developing ovarian cancer. Mutation carrier’s tumors contain nonfunctional BRCA1 or BRCA2 genes, which in healthy cells are involved in DNA repair. These tumors show an increased sensitivity to DNA damaging chemical agents and to PARP (poly(adenosine diphosphate-ribose) polymerase1) inhibitors. New targeted therapies already in use are directed toward tumors of mutation carriers. Successful treatment is most likely to be achieved through cooperation of a pathologist, oncologist and a genetic laboratory performing BRCA genes mutation screening.
Ključne riječi
Breast neoplasms – genetics, pathology, drug therapy; Genes, BRCA1; Genes, BRCA2; Mutation – genetics; Antineoplastic agents – pharmacology
Hrčak ID:
63558
URI
Datum izdavanja:
28.2.2010.
Posjeta: 4.019 *